AKAP9-Related Channelopathy: Novel Pathogenic Variant and Review of the Literature

Genes (Basel). 2022 Nov 20;13(11):2167. doi: 10.3390/genes13112167.

Abstract

Disease-associated pathogenic variants in the A-Kinase Anchor Protein 9 (AKAP9) (MIM *604001) have been recently identified in patients with autosomal dominant long QT syndrome 11 (MIM #611820), lethal arrhythmia (ventricular fibrillation, polymorphic ventricular tachycardia), Brugada syndrome, and sudden unexpected death. However, AKAP9 sequence variations were rarely reported and AKAP9 was classified as a "disputed evidence" gene to support disease causation due to the insufficient genetic evidence and a limited number of reported AKAP9-mutated patients. Here, we describe a 47-year-old male carrying a novel frameshift AKAP9 pathogenic variant who presented recurrent syncopal attacks and sudden cardiac arrest that required a semi-automatic external defibrillator implant and an electric shock treatment of ventricular arrhythmia. This study provides insight into the mechanism underlying cardiac arrest and confirms that AKAP9 loss-of-function variants predispose to serious, life-threatening ventricular arrhythmias.

Keywords: AKAP9 haploinsufficiency; long QT syndrome 11; novel frameshift; sudden cardiac arrest; variant.

Publication types

  • Review
  • Case Reports

MeSH terms

  • A Kinase Anchor Proteins / genetics
  • Arrhythmias, Cardiac / genetics
  • Brugada Syndrome* / genetics
  • Channelopathies* / complications
  • Cytoskeletal Proteins
  • Death, Sudden, Cardiac / etiology
  • Humans
  • Male
  • Middle Aged

Substances

  • A Kinase Anchor Proteins
  • AKAP9 protein, human
  • Cytoskeletal Proteins

Grants and funding

This research received no external funding.